Meeting
2021 ASCO Annual Meeting
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.
Authors
Janice Kim
U.S. Food and Drug Administration, Silver Spring, MD
Janice Kim , Diana Bradford , Somak Chatterjee , Pallavi Shruti Mishra-Kalyani , Yuan-Li Shen , Julia A. Beaver , Harpreet Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6078)
DOI
10.1200/JCO.2021.39.15_suppl.6078
Abstract #
6078
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
First Author: Lori J. Wirth
Poster
2022 ASCO Annual Meeting
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
First Author: Aaron Scott Mansfield
Poster
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
First Author: Caicun Zhou
Poster
2022 ASCO Annual Meeting
Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.
First Author: Or Kalchiem-Dekel